Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is certainly a buying opportunity. I believe come Q1 2014, no one will remember this funding at all! It'll be a temporary blip. I bought on this offering. Only wish I had more money to buy even more. I'm broke now for awhile, but happy to have picked up shares at this level. I never thought it possible so close to Trimesta results. All signs point toward a positive outcome there.
My best guess is that SYN will rise into Trimesta results. And any positive movement on C-diff will help the ascent. In fact, the word is getting out in that regard. Today, a shoutout in the WSJ!
http://online.wsj.com/news/articles/SB10001424052702304173704579262551354298622
I agree - I don't think it will stay red.
Heck, it was up to a new 52-week high today at $4.77. I still say $5 by EOW.
It won't dip down long enough to let me buy more!
Dang, already headed back up. Barely gives one a chance to pick up cheapies!!!
Wonder how many Sierra is buying. LOLOLOLOL!!! Many, I would presume.
I got many funds if this goes under $4. Well, many for me anyway! :)
What is going on with OMED could EASILY happen with GALE. Any day. Any time.
GALE is very undervalued, considering the pipeline and the Abstral sales that we all know will BEAT expectations.
Anything can happen at the conference, but the volume and PPS over the last few weeks would seem to indicate somebody knows something good!
I call $5 by EOW. Buying on all dips!!!
From the conference call:
"I would like to let everyone know that we were pleased to announce today that SYN-004, our candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in infectious disease area by Elsevier Business Intelligence. And related to this, we will be presenting at the 2013 Therapeutic Area Partnerships Conference next Tuesday, November 19, in Boston. As we look forward, we will also be presenting at the LD Micro Conference in early December out in LA." - Kris Maly (Communications)
This is excellent news!
Also, Riley spoke of Trimesta as being the most current impending value driver. The study officially ends in December with results due out 1H 2014. Only so much time to get in at these levels, IMO. The slight whiff of good news, combined with the low float, sends SYN to the moon. IMO
NEWS OUT! in the Wall Street Journal no less!
Amarantus and Brewer Sports Announce 2nd #C4CT Concussion Awareness Summit Surrounding Super Bowl XLVIII
Summit Will Feature Sports and Neurology Experts Discussing the Potential Link Between MTBI and CTE
MINNEAPOLIS and SAN FRANCISCO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company developing new treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis, and Brewer Sports International (BSI), a multi-faceted global sports advisory firm, have announced the date for the Amarantus BioScience #C4CT Summit hosted by Brewer Sports International, powered by MDM Worldwide on Wednesday January 29(th) , 2014 at the United Nations in New York City, NY.
The #C4CT (Coalition for Concussion Treatment) Summit will focus on important scientific, medical, translational and prevention-related topics of Mild Traumatic Brain Injuries (MTBI) and the potential link in the transition Chronic Traumatic Encephalopathy (CTE). Conference panels will include industry experts from AMBS, Banyan Biomarkers, Cerora and more joined by international business leaders and current and former professional athletes.
"MTBI and their potentially fatal side effects, including CTE, in amateur and professional athletes are emerging as a major point of discussion in mainstream media because of the current impact on football, hockey and other sports," said Gerald E. Commissiong, President and CEO of AMBS. "As a former athlete, I understand the need to balance safety and prevention with the desire to play and the positive impact sports can have for individuals and society as a whole. We are proud to be the first group to unite the different stakeholders in the concussion debate and believe the United Nations will set the stage for this truly global discussion."
The #C4CT Summit will include presentations and panel discussions on the following key topics:
1. Chronic Traumatic Encephalopathy: What is it? Medical and Pathological
Perspective
2. Standard of Care in Treating Multiple Concussions
3. NFL Settlement Discussion and the Future of Contact Sports
4. Diagnostic Tools and Potential Therapies Under Investigation
5. Current and Former Professional Athlete Stories and Perspectives Jack Brewer, CEO of BSI, explains, "The advances in concussion research and treatment over the past year have been more substantial than any other time in history. Awareness has been steadily growing through various documentaries, media reports and investigational studies. Instead of focusing on pointing fingers and finding those to blame, our firm is dedicating time and resources to identifying and spreading awareness about innovative treatments and solutions to the actual problem."
In June, BSI and AMBS held the inaugural #C4CT Summit in Minneapolis as a part of the two-day Brewer Sports Symposium. The summit focused on the scientific understanding of TBI and its long-term implications as well as current medical practices and new approaches being considered. The event included speakers such as Dr. Robert Cantu, Super Agent Leigh Steinberg and former NFL athletes Robert Griffith, Thomas Jones, Barrett Green and others. Panelists focused on new technologies, services and how concussions affect athletes.
About Amarantus BioScience, Inc.
Amarantus is a development-stage biotechnology company focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to the therapeutic protein Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for various protein folding-related medical conditions. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), in collaboration with Brewer Sports International raising awareness of new products in development for concussions and traumatic brain injury. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Brewer Sports International (BSI) is a multi-faceted sports advisory firm within The Brewer Group Companies with a focus on the business of sports, wellness and media for professional athletes, sports agencies, public and private corporations and various partners including international organizations, governments and NGOs. Based in Minneapolis, with offices in New York, Dallas, Miami, Beijing and Malawi, BSI was founded by Jack Brewer, a five-year National Football League (NFL) veteran and former team captain on three NFL teams. Additionally, BSI has created a unique financial services platform that is offered to professional athletes and sports agencies, as well as high net worth individuals and businesses touching professional sports. BSI takes pride in enabling its clients to capitalize on the endless opportunities presented through sport. For more information, please visit www.brewersports.com or follow them on Twitter, Facebook and LinkedIn.
About MDM Worldwide
MDM Worldwide Solutions, Inc. is a digital communications agency that develops and manages online engagement strategies to connect companies with their stakeholders. MDM specializes in working with clients in the technology, healthcare and life sciences spaces. MDM's vast industry knowledge, proprietary methodology, proven track record and experienced leadership team enables them to create and customize targeted digital marketing campaigns to fulfill all of their clients' objectives. For more information, please visit http://mdmworldwide.com/ or find them on Facebook, Twitter, Google+ and LinkedIn.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Russell Miller, Director of Investor Relations
408.737.2734 x 109
ir@amarantus.com
Brewer Sports International:
Danielle Berman, Director of Business Development and Media
Danielle.Berman@thebrewergroup.com
(443) 841-4667
It's 'due' not 'do.
You said correct you if you were wrong!!! LOL
Actually, the trial ends at the end of 2013. Results are due 1H 2014. It's anyone's guess how soon SYN will put out something 'official'.
Unofficially, many of us have been in contact with the patients or the sites doing the testing. And there seems to be clear evidence of certain patients doing FAR better than others -- to the point where they KNOW if they've gotten Trimesta or not. Or they feel they know, anyway.
All indications are that it WORKS. And we already know it's safe and tolerable.
Trimesta success alone puts SYN at $5 ++ in my opinion.
Then there is SYN-004, the C-diff wildcard. We could get info on that one any time.
And of course, flupertine -- again, we don't control the timing, so it could be whenever.
SYN has pretty intersting things in the pipeline, but if I were loading up (and I AM), I wouldn't wait much longer. I would definitely do it in 2013 to be sure I was in BEFORE results come.
How you invest is up to you. You can sell the news or the run-up to the news. But I'm holding through the news. I see all signs as good and positive and eventually moving SYN up with the bigger boys.
Right now, there is big time accumulation. It's most like MMs or traders who don't pay themselves commissions because they are flipping it out for a lower cost basis -- it would appear anyway. I am just riding along with them, buying when it looks good, knowing the up ticks and the down ticks have no rhyme or reason but their intent to lock it in within a range. I could write their procedure manuals!! And all the ask whacks. Very funny stuff! They can only do this for so long, with the low float.
When news hits, and with the low float, LOOK OUT ABOVE! It will be the big jumps of days past. And I can't wait for watch it!!
GLTAL
Welcome back BioChica!
Trimesta and SYN-004 moving SYN. It was only a matter of time. I've loaded up quite nicely when there was no activity. Someone else has been quiety accumulating (looks like they still are!). We all knew Q4 and 1H 2014 was going to be stellar. And so it begins.
Just another someone who finally sees the light (but my guess is we'll blow past $3 pretty quick!) ...http://www.streetinsider.com/Hot+New+Coverage/Maxim+Group+Starts+Synthetic+Biologics+(SYN)+at+Buy/8730798.html
Good luck to all -- especially we longs!!
Go SYN!
Couldn't agree more about AMBS potential!
Nice move today. Lots of nice moves lately. The market is digesting the new financing and appears to be coming to the same conclusion as us.
Holding and picking up more on dips.
AMBS is the best kept biotech secret!
This financing is great news. Now AMBS has some breathing room to focus on developing its products. Love the no shorting provision. Great deal for Dominion and for AMBS -- all around.
Picking up shares today!
This financing is great news. Now AMBS has some breathing room to focus on developing its products. Love the no shorting provision. Great deal for Dominion and for AMBS -- all around.
Picking up shares today!
Looks like Cleveland is the next Clearvision airport going up!
http://www.digitalsignagetoday.com/article/216493/Clear-Channel-Airports-launching-in-airport-digital-signage-TV-channel
Nice moves up this week. Let's keep it going!
Well now, here we go. Think someone knew this? Was wondering about the ramp up yesterday. MMs are constantly working to keep this down, quietly accumulating MORE shares. It's so obvious.
Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
-- FUJIFILM Diosynth Biotechnologies UK Limited to Evaluate Expression of Company's Proprietary Beta-Lactamase Enzyme, SYN-004 --
ROCKVILLE, Md., July 18, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the initiation of the manufacturing process of the Company's proprietary beta-lactamase enzyme (SYN-004) to target the prevention of Clostridium difficile (C. difficile or C. diff) infections. Pursuant to an agreement with FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), the initial phase of the SYN-004 manufacturing process is underway with the evaluation of beta-lactamase protein expression in Fujifilm's pAVEway™ platform. SYN-004 will be evaluated for production cell line yields as well as biological activity of the enzyme product.
"Initiating this expression platform evaluation with Fujifilm is an important first step in the SYN-004 manufacturing process. These efforts move us toward our goal of developing a prophylactic to prevent the devastating effects of C. diff infections, for which there is currently no vaccine or other approved preventive therapy," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "Upon completion of production cell line evaluation and selection of the optimal expression clone, we intend to proceed rapidly with manufacturing of preclinical material for animal studies, and cGMP production of SYN-004 for clinical studies."
Steve Bagshaw, Managing Director of Fujifilm Diosynth Biotechnologies UK Limited said, "We are excited to have the opportunity to demonstrate to Synthetic Biologics the versatility of our pAVEway™ expression system for SYN-004 production."
SYN-004: Targeting the Prevention of C. difficile Infections
In November 2012, Synthetic Biologics, Inc. acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of C. difficile infections (CDI), the leading cause of hospital acquired infections (HAI), that generally occur secondary to treatment with intravenous antibiotics. The acquired assets include a pre-Investigational New Drug (IND) package for SYN-004, a 2nd generation oral enzyme candidate (formerly known as Ipsat Therapeutics P3A); Phase I and Phase II clinical data for P1A (a 1st generation oral enzyme candidate); manufacturing processes and data; and, a portfolio of issued and pending U.S. and international patents intended to support an IND and Biologic License Application (BLA) with the U.S. Food and Drug Administration.
Utilizing this portfolio of assets, the Company intends to develop a proprietary oral beta-lactamase enzyme product candidate, SYN-004. When co-administered with certain intravenous beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract, thus preserving the natural balance of the patient's microflora, and preventing opportunistic infections including CDI. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics. In 2012, 15 million Americans were administered beta-lactam antibiotics.*
Compared to the 1st generation oral enzyme candidate, P1A, the Company believes that SYN-004 will be able to degrade a broader spectrum of beta-lactam antibiotics, including both penicillins and cephalosporins. Due to the structural similarities between P1A and SYN-004 for the prevention of CDI, along with previous discussions with the FDA, it is anticipated that certain preclinical data collected on P1A may be used in support of an IND for the Company's new product candidate, SYN-004.
About Clostridium difficile (C. difficile) Infections
According to the Agency for Healthcare Research and Quality, aggregate costs associated with CDI-related stays in the hospital were $8.2 billion in the U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by C. difficile bacteria result in diarrhea (C. difficile-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death. CDI is a major, unintended risk associated with the prophylactic or therapeutic use of intravenous antibiotics, which may alter the natural balance of microflora that normally protect the GI tract, leading to C. difficile overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.
CDI is a widespread and often drug resistant infectious disease, and it is estimated that 1.1 million patients are infected with C. diff annually in the U.S.* Controlling the spread of CDI has proven challenging, as the C. difficile spores are easily transferred to patients via normal contact with healthcare personnel and other inanimate objects. There is currently no vaccine or approved product for the prevention of C. diff infection.
About Fujifilm Diosynth Biotechnologies (http://www.fujifilmdiosynth.com)
FUJIFILM Diosynth Biotechnologies UK Limited is an industry leading biologics Contract Development and Manufacturing Organization. Fujifilm Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from microbial and mammalian cell line development, including its proprietary pAVEway™ system, to process development, analytical development, clinical and commercial manufacturing. Fujifilm Diosynth Biotechnologies is also located in Research Triangle Park, NC, USA as FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Both sites have been FDA-approved for the production of commercial biologic products.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.
This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our intention to develop and commercialize a proprietary oral beta-lactamase enzyme product candidate using the acquired assets that will have the desired results, our intention to commence clinical trials and the expected size of the market for C. diff therapeutics. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, our inability to timely commence or complete the clinical trials consistent with our current expectations and our inability to successfully develop, receive regulatory approvals for or to commercialize a new product candidate to prevent C. diff infection and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2012 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
*This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.
SOURCE Synthetic Biologics, Inc.
For further information: Kris Maly, Vice President, Corporate Communication, (734) 332-7800, ext. 22
To unsubscribe or change your settings click here:
http://www.syntheticbiologics.com/index.php?s=subscribe&code=YqJrKJpzpubwDm7HurZIo5fN5ZypGHA=
Love it! Love it! Love it!!!!!
Go PNCH!!
IC Punch Media, Inc. Owners of The VU Television Network Announce Content and Co-Production with China's JP Investment Advisors Ltd. Beijing.
By IC Punch Media, Inc.
Published: Monday, Jun. 24, 2013 - 5:10 am
HOLLYWOOD, Calif., June 24, 2013 -- /PRNewswire/ -- IC Punch Media, Inc. (OTCQB: PNCH) announces today it has signed a Letter of Intent with JP Investment Advisors Ltd., Chaoyang District, Beijing, China for funding and co-production of certain entertainment technologies, motion picture and television projects.
Writer, Director, Bennett Davlin, who wrote the $40M action comedy, "The Medallion" starring Jackie Chan and Claire Forlani, brings his long awaited one-hour drama series, "GARDEN 1.0" through his producing relationship with VU Television Network President Gayle Dickie, for the Chinese co -production. "Bennett and I have worked together on and off for a number of years to make this incredible series a reality and now that we have the support of our Beijing associates and producers, the timing couldn't be more perfect."
"Garden 1.0" was designed to be so complex that the Game World becomes REAL. Garden 1.0 is modeled after the 217 million people who play online, downloadable, and console video games. This captivating one-hour series will focus on the concept of being lost inside the most popular videogame where we follow six friends who have never met in the flesh.
CEO Steve Samblis stated, "When Gayle first approached me with the Garden 1.0 series, the concept was mindboggling and fascinating. I'll go on record to state this series will be a break out hit for China, our VU Television Network and the world. Shooting the series in China and funded by our Chinese Partners will create an extraordinary show. I'm also very excited about working with our new Chinese partners and building a strong long-term relationship. "
Garden 1.0 lends itself to the lucrative gaming industry. The series already has Chris Taylor, "Gas Powered Games" CEO as their technical advisor, who will ultimately lead the charge for a video game based upon the series. Taylor is one of the leading computer game designers and entrepreneurs, most famous for developing Total Annihilation and the Dungeon Siege series.
Bennett Davlin commented, "I really was waiting for the right partners at the right time. Now that VU Television Network , Chris Taylor and China have come together to support my series, I'll have the opportunity to work once again in China. It's like going home for me."
VU Television Network Officers and JP Investment Advisors Ltd. are scheduled to meet in Beijing in late July to collaborate on various television projects that would be suitable for the China television marketplace. Principals of both companies held meetings in the U.S. in June of this year. Both parties are currently working out the terms and conditions for financing, distribution and production services for IC Punch Media, Inc. and their VU Television Network.
VU Television Network is currently developing multiple reality series and one-hour dramas as well as programming and content consisting of launch related specials, comedy, local entertainment news, and family friendly movies along with children's programming for morning weekday and weekend time periods.
VU Television Network is launching late September of 2013 in 30% of the domestic broadcast market, national cable, and the Out-Of-Home Distribution (OOHD) markets. All of VU Television Network shows will also offer some interstitial spots and cross platform promotion, which will air on the www.icplaces.com websites, which are currently in over 350 cities across the U.S. The company aims to enhance viewership of the show by capitalizing on its multi-media platform especially with its OOHD footprint, which is, unparalleled by any other network today.
About IC Punch Media, Inc. IC Punch Media, Inc. is a trans media entertainment complex that produces entertainment content for distribution across multiple mediums. The company trades on the OTCQB: Symbol PNCH. (http://www.icplaces.com)
Through multiple long-term partnerships, clips and full episodes of the company's shows are available to people outside the traditional set top box. This exposure serves as both a profit center and marketing component promoting the TV Network, its line up and the company's new media specific programming across multiple platforms.
IC Places Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
IC Punch Media, Inc. 407-442-0309 Ext2 info@icplaces.com
Web site: http://www.icplaces.com/
SOURCE IC Punch Media, Inc.
Read more here: http://www.sacbee.com/2013/06/24/5519186/ic-punch-media-inc-owners-of-the.html#storylink=cpy
NEWS OUT!!!
IC Punch Media Inc. Announces Docu-Drama Series “First Responders” to add to VU Television Network Launch
[ACCESSWIRE] Hollywood, CA, 6/21/2013 8:12:00 AM - IC Punch Media, Inc. (OTCQB: PNCH) announces today their first docu-drama series, “Code 9” (Officer Needs Assistance) which will address the increasing problem of Post Traumatic Stress Disorder for police, fire, dispatchers, EMT’s and correction officers not only in the U.S., all over the world. The series will explore this growing difficulty for officers and their families who suffer the mental anguish for the careers they choose.
Hundreds of articles and videos have been produced with the worn out advice of “Get help when you need it.” This series aims to enlighten viewers, victims and their families to prepare as early as their first training day begins in their profession. Taking away the stigma and shame of emotional trauma is an important issue and challenge for the men and women who serve as our ‘first responders’ and public service officers.
“With over 26 hours of gripping interviews available, we believe we can help produce a compelling series and/or special to shed light on resources for this widespread injury, and give hope to first responders all over the world,” offered VU TV Network President Gayle Dickie.
VU Television has entered into an agreement to develop and produce 13 half hours for a series to air late fall 2013. Dangerous Curves Productions Deborah Louis Ortiz comments, “We are also discussing the possibility of also producing a 90 minute special to kick off the series. I’m so thankful to finally bring this message of hope out to the world.”
VU Television Network is currently developing multiple reality series and one-hour dramas as well as programming and content consisting of launch related specials, comedy, local entertainment news, and family friendly movies along with children's programming for morning weekday and weekend time periods.
VU Television is launching late September of 2013 in 30% of the domestic broadcast market, national cable, and the Out-Of-Home Distribution (OOHD) markets. “Code 9" will also offer some interstitial spots and cross platform promotion, which will air on the www.icplaces.com websites, which are currently in over 350 cities across the U.S. The company aims to enhance viewership of the show by capitalizing on its multi-media platform.
About IC Punch Media, Inc.
IC Punch Media, Inc. is a trans media entertainment complex that produces entertainment content for distribution across multiple mediums. The company trades on the OTCQB: Symbol PNCH. (http://www.icplaces.com)
Through multiple long-term partnerships, clips and full episodes of the company's shows are available to people outside the traditional set top box. This exposure serves as both a profit center and marketing component promoting the TV Network, its line up and the company's new media specific programming across multiple platforms.
IC Places Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
IC Punch Media, Inc.
407-442-0309 Ext2
info@icplaces.com
Web site: http://www.icplaces.com/
NEWS!!!
Can't be spun or manipulated to be anything but POSITIVE, IMO.
Amarantus Reports Positive Results on MANF Neuroprotective Properties Demonstrated in Preclinical Study in China
Category: Proteins and Peptides| Published on Wednesday, 19 June 2013 18:16 | Hits: 15 |
SUNNYVALE, CA, USA I June 19, 2013 I Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, announces that positive neuroprotective properties for the Company’s MANF therapeutic were reported in a preclinical research study conducted by the Department of Orthopaedics at Qilu Hospital of Shandong University, in Jinan, China. Specifically, a published abstract of the study concluded, “These findings demonstrate that MANF shows the potential to alleviate cell damage and inflammation in rat primary astrocytes by suppressing ER (endoplasmic reticulum) stress, indicating that MANF plays an important role in astrocyte inflammation and functioning and may suggest a promising strategy for neuroprotection in the central nervous system.”
“The findings from the study at Shandong University are consistent with the results we obtained in our own research with MANF on rat models for Parkinson’s disease, which were reported in March 2013,” said John W. Commissiong, Ph.D., Chief Scientific Officer of Amarantus. “We are very pleased that independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson’s disease. We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”
An abstract of the research report titled “Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Oxygen-Glucose Deprivation-Induced Cell Damage and Inflammation by Suppressing Endoplasmic Reticulum Stress in Rat Primary Astrocytes,” was e-published in the Journal of Molecular Neuroscience, and is available at http://www.ncbi.nlm.nih.gov/pubmed/23760988. Glucose and oxygen deprivation is a common factor in conditions involving reduced blood flow to the brain. This places energy stress on cells such as astrocytes, which then become damaged, functionally impaired or even die. Release of inflammatory mediators from stressed astrocytes causes further damage to neurons, with resulting neurological impairment. The work from Shandong University suggests MANF may protect against such neurological damage by suppressing these pro-inflammatory changes in astrocytes.
The research abstract stated, “This current study investigates whether mesencephalic astrocyte-derived neurotrophic factor (MANF) inhibits oxygen-glucose deprivation (OGD)-induced cell damage and inflammatory cytokine secretion by suppressing endoplasmic reticulum stress in rat primary astrocytes. We found that MANF alleviated OGD-induced astrocyte damage and rescued the cell viability, and the upregulation of GRP78 (endoplasmic reticulum (ER) stress marker) and NF-?B p65 (one of the central mediators of proinflammatory pathways) induced by OGD were significantly reduced by preincubation of MANF. In addition, the increases of secretion and mRNA expression levels of the proinflammatory cytokines IL-1ß, IL-6, and TNF-a in astrocytes induced by OGD were significantly suppressed by MANF.”
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases for which MANF is currently being evaluated.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.
SOURCE: Amarantus
Fantastic news! One after the other with the new shows being announced this week! Looking VERY forward to the launch in September! In a very short period of time, VU has done MORE than Punch TV ever could! And the programming is much more diverse too!!
IC Punch Media Inc. Announces Acquisition of 2 New Children’s Shows - “Nanalan” and “Jurassic Cubs” For VU Television
IC Punch Media, Inc. Hollywood, CA (OTCQB: PNCH) announces today the start of the children’s programming lineup. “Nanalan” is an award winning Best Performance and Best Writing for a Pre-School Series out of Canada, designed to foster children’s curiosity and love of learning to carry with them as they grow. With 44 half-hour episodes produced, the show’s main protagonist, 3 year-old Mona spends her weekdays with her Grandmother aka “Nana” with frequent visits to next door neighbor, Mr. Wooka, and his dog, Russell, learning, playing and exploring.
Also in the new children’s lineup is Jurassic Cubs, a highly successful kids series from Animundi! Italy, and top rated in more than 10 countries worldwide. Jurassic Cubs is a half-hour 2D action-edutainment animated series that features five dinosaur cubs, Bronto, Ranu, Saro, Stego and Nunzy. With the help of Saùro an old and learned shaman, capable of visualizing past and future in the Magic Fountain, the cubs discover their true powers within. And, after having found their parents, the Jurassic Cubs face a new threat: T-3000, a most dangerous robot coming from the future. The protagonists, Black Meteorites and Dr. Tauras pursue the secret of time traveling while the Jurassic Cubs extraordinary adventures struggle and persevere with the two true super-villains.
“We are very pleased to announce the beginning of our young children’s programming block, specifically for the 2-6 year olds.” VU TV Network President Gayle Dickie commented, “Both “Nanalan” and “Jurassic Cubs” are highly entertaining and educational shows for our youngest viewers which will help kick off our launch in September.” Steve Samblis, CEO of IC Punch Media states, “We are very aware of our obligation to provide quality family programming and with Nanalan and Jurassic Cubs as our first offering, I’m very happy that we have these shows to jump start our VU Television Kids Block in September. ”
VU Television Network is currently developing multiple reality series and one-hour dramas as well as programming and content consisting of launch related specials, comedy, local entertainment news, and family friendly movies along with children's programming for morning weekday and weekend time periods.
VU Television is launching late September of 2013 in 30% of the domestic broadcast market, national cable, and the Out-Of-Home Distribution (OOHD) markets. “The Hollywood Judge” shows will also offer some interstitial spots and cross platform promotion, which will air on the www.icplaces.com websites, which are currently in over 350 cities across the
U.S. The company aims to enhance viewership of the show by capitalizing on its multi-media platform.
http://www.icplaces.com/los-angeles/ic-punch-...2%80%9D-vu
Buying under a buck is NEVER a mistake with SYN. I'd say buying anything under $2 is OK too!! Trimesta alone is worth $5 ++, IMO.
Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
-- Keynote Speaker, Rhonda R. Voskuhl, M.D., Director of the Multiple Sclerosis Program at UCLA, to Address the Role of Estriol in the Treatment of Multiple Sclerosis --
ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York City. This event will be accessible via a live webcast through the following internet link, https://viavid.webcasts.com/starthere.jsp?ei=1018556.
Keynote speaker, Rhonda R. Voskuhl, M.D., will join Synthetic Biologics' executive management remotely for the presentations. Dr. Voskuhl is Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA School of Medicine, and the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS). An overview of MS and the current market, as well as the history of estriol and its role in the treatment of MS will be discussed.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations
mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.
The good news for PNCH keeps coming! Sept. launch of VU Television with new and interesting shows. (And 25% of shares to be retired!!!) Back over a penny soon, IMO.
"HOLLYWOOD, Calif., June 12, 2013 /PRNewswire/ -- IC Punch Media, Inc. (PNCH) announced today it has acquired forty (40) episodes of "The Hollywood Judge" to be aired this fall. Produced by Emmy Award Winning James Allen Bradley and Sammy Riotti, this is not your typical Judge show. This weekly 30-minute show puts Hollywood celebrities and reality stars in a courtroom setting to resolve their differences in a fast paced dramatic and often comedic style. The Honorable Judge Mark Fidel presides over cases with a direct and often humorous tone. Carmen Polombro conducts the post trial interviews.
VU TV Network President Gayle Dickie remarked, "There's always a good audience on hand for courtroom type shows and The Hollywood Judge adds a bit of a celebrity slant to the mix that is entertaining and sometimes jaw dropping, perfect for late fringe time periods." Steve Samblis, CEO of IC Punch Media also commented, "I'm a big proponent of entertainment type programming and The Hollywood Judge is very engaging with a unique offering for late night viewers."
Created by James Allen Bradley and Sammy Riotti, the "The Hollywood Judge" boasts a bonanza of reality stars including Daniel Baldwin, Erick Estrada, Carney and Wendy Wilson, Ron Jeremy, Prince Von Anhalt and Bobby Trendy, just to name a few. Bradley added, "We are pleased to announce we are already planning our Season 2."
VU Television Network is currently developing multiple reality series and one-hour dramas as well as programming and content consisting of launch related specials, comedy, local entertainment news, and family friendly movies along with children's programming for morning weekday and weekend time periods.
VU Television is launching late September of 2013 in 30% of the domestic broadcast market, national cable, and the Out-Of-Home Distribution (OOHD) markets. "The Hollywood Judge" shows will also offer some interstitial spots and cross platform promotion, which will air on the www.icplaces.com websites, which are currently in over 350 cities across the U.S. The company aims to enhance viewership of the show by capitalizing on its multi-media platform.
About IC Punch Media, Inc.
IC Punch Media, Inc. is a trans media entertainment complex that produces entertainment content for distribution across multiple mediums. The company trades on the OTCQB: Symbol PNCH. (http://www.icplaces.com )
Through multiple long-term partnerships, clips and full episodes of the company's shows are available to people outside the traditional set top box. This exposure serves as both a profit center and marketing component promoting the TV Network, its line up and the company's new media specific programming across multiple platforms.
IC Places Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise."
Looking like something about to start here!
Orbit Stocks and Mega Penny Stock Pick promoting AMBS tonight.
THIS: "We are issuing an alert on AMBS tonight because we are hearing rumors of some big things coming her way!
AMBS chart is set to blast off here, and any catalyst will make her shoot up.
AMBS is one of those bio-tech plays that may very well make it to the big leagues...and we all know what that means!...."
AND THIS:
"Amarantus BioScience Holdings, Inc. (AMBS) is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.
Neurodegenerative diseases such as Parkinson’s, ALS and Alzheimer’s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s Disease and other human diseases.
Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. The Company also has a diagnostic program led by NuroPro® which is aimed at developing diagnostic blood tests that are capable of early identification of apoptosis-related medical conditions while tracking their progression over time.
Amarantus’ Management Team and Board of Advisors have designed a business strategy to formulate and advance pre-clinical and clinical programs for the Company's product candidates through successive de-risking milestones in order to maximize their commercial potential. The Company is also focused on making the assets attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.
Amarantus BioScience Holdings, Inc.(AMBS) intends to advance its therapies and diagnostics to provide patients with safe and effective treatment options in the care of their chronic illnesses
For More information about AMBS, Visit the company's website www.amarantus.com
Happy Trading"
Big things happening with PNCH. The recent PRs indicate things are heading in the right direction. Up 20% today so far. Interest seems to be building again. Nice big buy at .0015 (which oddly enough happened after a questionable close at .0015 the prior day). Someone (or some MM) seems to have wanted in badly.
I think the newly PR'd shows sound very interesting and could be big.
And with the impending retiring of approx. 25% of the shares, the PPS should go up nicely.
DOOH seems to be heating up for PNCH as well. Interesting new cover photo. Makes you wonder what might be happening behind-the-scenes.
I'm locked and loaded for some big PNCH gains!
GLTAL
Exactly!
This week should be very good.
Positive release last week. Should be another positive release this week. Shares paid for Punch and JC's employment will be retired.
New people in place (THANK GOD!!!), new focus (THANK GOD!!!) and a new vision set to go live this Fall.
In the meantime, we still have the IC Places websites up and running and Clearvision installed in 3 airports with at least another 1 per month for the remainder of the year. In fact, we are due to hear about another one any time now!
I believe the bottom has been set and it's up from here on any whiff of good news at all.
GLTAL
My one post:
We've got a fake 'news' site spewing rumors --- an obvious attempted takedown, very BADLY timed. LOL
We've got unpaid promos.
We've got a triple bottom.
We've got an impending golden cross.
We've got the upcoming Q.
And we've got another airport up and running!!!!
Hello DALLAS!!! http://www.digitalsignageconnection.com/digital-out-home-airport-tv-network-takes-dallas-love-field-887
Go PNCH!!!
GLTAL
By all accounts, yesterday's shareholder meeting and upfront were wildly successful! PNCH is a strong and growing business. Pictures of the event were AMAZING! People waiting in line to get in.
Delays in the K were satisfactorily explained. And the K will be out later today, for anyone interested in REAL financials (versus speculation).
But more importantly, it's the upcoming Q. And the Q after that. And the Q after that. And so on. Steve said so himself. Revenues will continue to grow. Start-up related expenses will decline. PNCH will start becoming profitable and the PPS will reflect it.
Revs are increasing. PNCH is expanding it reach and it's advertisers. Clearvision is moving right along! http://www.airport-world.com/home/general-news/item/2535-new-clear-channel-airport-tv-network-takes-shape-in-us
More airports will sign once they see what Clearvision has to offer versus tired, old and biased CNN.
What PNCH does today or tomorrow or this week really doesn't matter -- not to anyone who is a long term holder and has vision. Long terms can't be shaken out. So buy and sell to yourselves!!! Still can't have my shares.
GLTAL
So true -- smaller stations are cutting in to the big networks big time! Enough to take notice anyway.
Smaller, edgier, targeted to the urban crowd!
I expect BIG things from PNCH TV!!!
PNCH is going to be H-U-G-E and bring holders mucho dinero!
All IMO, of course.
Just watch the charts! They tell a beautiful story.
GLTAL
PNCH is doing so many great things. And the chart looks surprisingly like it did last year at this time, right before the mega run to nearly .06!!!
4 green days in a row and counting.
Soon to see the K -- the one Steve says is the best he's ever worked on.
It's due right before the 1st PNCH Shareholder Meeting!
Soon thereafter, we'll see results from Q1.
At least 10 more airports are due up this year. When travelers get to see Travel Tech -- look out! What an amazing show reaching an affluent and captive audience.
I know I bought more today.
Are you thirsty yet?!
Go PNCH!!!!
That's the spirit! I feel for those who are engaged here -- it's gotten beyond worthwhile for me.
I did want to use my ONE POST to say THANK YOU to whomever sold me more shares today!
I have complete confidence in my purchases and know these shares that you were kind enough to sell to me will be worth multiples in the near future.
I expected some attempts today to bring the price down -- of course, it's a holiday weekend. Flippers and daytraders can't go 3 whole days without beer money! LOL So the downward push is there. I took advantage of it.
Looking very forward to the 'best K ever', and particularly the upcoming Q and shareholder's meeting.
Know what you own! And understand why some try to convince you otherwise.
GLTAL
P.S. Please don't respond to this. I won't read it. And please don't PM me elsewhere!
Your group is not the only one! Though your efforts are certainly appreciated. :)
It's a lovely shade of green this morning, don't you think?
Up 36% -- that's gotta put the hurtin' on those who are calling for red.
Big money says it's staying green today. ;) :)
Thanks for the cheapies!!! I've got to give credit to the boys who made it happen. Credit where credit is due!! Thank you!!
Watch out for below-the-bid trades traders -- that's when you KNOW the market sentiment is BUY and the MMs are running scared. We saw that a lot the last two days -- which is why I knew we'd be going green real soon!
True buys versus the fake trades rule the day!!!
Nice to have big interest in the Shareholder's meeting -- so much so the venue had to be changed to something roomier. Likin' it! Likin' it very much.
GLTAL
So true, tradewin!
My one post today is to let the manipulators know that they can keep selling to themselves and snagging other people's shares via stop losses and panic. LOL
I do feel sorry for those who don't know how to ignore or play these kinds of days.
PNCH is a growing company. Nothing is causing this downturn except an unscrupulous (and BTW telegraphed!) bear raid. We all know how it plays and the players, don't we?
You want my shares??? Molon labe! LOL Yeah, just try.
Know what you own -- I do!
PNCH - like you OWN it
GLTAL
I agree - PNCH is a steal at these levels.
Yes, there was good news today. We can see that the Clearvision deal is proceeding as planned with another 10 airports scheduled this year. With the acquisition of PNCH, they are now producing their own content. And with the new studio, production quality has been steadily rising! Travel Tech is an AWESOME show, an advertiser's DREAM SHOW actually.
With the one post I have today, it is important to note that these orchestrated PPS takedowns are to be expected. Shaking out the weak hands, those with fib stops, etc. is par for the course. If investors do not have the fortitude to wait until the K, the Q1 and the shareholders meeting, they should go. When PNCH bounces, as it WILL, you might not get back in at the level you'd like. Selling now is, IMO, a huge gamble. The trend is up and up for a reason. There is also a reason MMs and brokers have no shares, put up blocks by telling investors there are no shares to buy but only to sell. Can you say 'CYA'?
Well, they can cover with OPS (other people's shares!), not mine.
Good luck to all and know what you own!
Raleigh-Durham International Airport Launches ClearVision Airport TV Network For Travelers and Advertisers
Clear Channel Airports' New TV Network Launches in Second International Airport To Deliver the Best Entertainment Experience to RDU's 9.2 Million Annual Travelers
ALLENTOWN, Pa., March 25, 2013 /PRNewswire/ -- Clear Channel Airports (CCA), a division of Clear Channel Outdoor Holdings, Inc. (NYSE: CCO), and the world's leading marketer of airport advertising, today announced the launch of ClearVision airport television network in the Raleigh-Durham International Airport. With the February unveiling of ClearVision in the Louis Armstrong New Orleans International Airport, RDU's installation marks the second international airport to offer its travelers rich local news, music and sports programming from more than 140 content partners carried by ClearVision. The new network enhances the experience for travelers and offers advertisers a valuable new medium for reaching highly desirable business and leisure travelers.
Welcoming more than 9.2 million travelers in 2012, RDU is the gateway to three of the best universities in the country, a world-renowned high-tech community in Research Triangle Park and a number of tourist attractions ranging from the mountains of western North Carolina to the Atlantic coast. "For the more than nine million passengers who travel through RDU each year, our airport is the first and last impression they are left with when visiting the Research Triangle Region," said RDU Airport Director, Michael Landguth . "Launching ClearVision gives us the opportunity to keep up with the tech-savvy population and communicate with travelers about all that our region has to offer."
RDU now offers passengers the best mix of programming through ClearVision's growing number of well-known content partners, such as:
• Entertainment
o Access Hollywood, Bravo, CBS, CelebTV, C-Net, Cooking Channel, E!, DIY, Fox, Game Show Network, HGTV, NBC, Style Network, Travel Channel, Funimation
• National and local news sources
o The region's own WRAL will provide local news. Other news sources include ABC, Associated Press, CBS, Dow Jones, Freshwire, FOX Business News, NBC, WSJ, and Weather Channel
• Music
o Blastro Networks, Billboard magazine, FILTER magazine, VH1, Universal Music Group, Columbia Records, Disney Records
• Sports
o Golf Channel, Indycar, LPGA, MLB, NAUTICAL CHANNEL, NBC Sports, PGA Tour, Universal Sports
"Consumer desire for fast, compact video information and entertainment is growing at a rapid pace, especially at airports; ClearVision's shortened versions of popular shows, news and events directly address this opportunity," said Clear Channel Airports' President Toby Sturek . "ClearVision now gives travelers a more varied video entertainment experience while waiting in the airport. Its launch represents a huge step in delivering the information and entertainment that travelers constantly want, while also providing advertisers a dynamic platform for reaching engaged audiences."
In addition to entertaining travelers, the ClearVision platform provides global and national advertisers a dynamic medium for branding products and services to very valuable consumers – frequent travelers. On the local side, ClearVision is ideal for airports of cities seeking to promote hometown businesses and tourism in order to lift sales tax revenue and encourage repeat visits. Additionally ClearVision gives airports the capability to incorporate customized messages within the programmed content, helping them to better connect with visitors and enhance their experience.
ClearVision was created through a partnership between Clear Channel Airports and connectiVISION Digital Networks, a leading digital media company. "Our venture with Clear Channel Airports is the first of its kind in the Television Network arena - bringing to life customized television stations in each ClearVision airport. ClearVision follows the tenants of traditional television with a day-parted schedule featuring morning, daytime, primetime and late night programming in a dynamic line-up that is designed to entertain, inform and educate a world on-the-go," said David Tetreault , COO of ClearVision/ConnectiVISION.
Together Clear Channel Airports and connectiVISION are building momentum among U.S. airports and transforming in-airport advertising. "The power of the ClearVision medium is ideal for Fortune 500 brands, offering the ultimate connection point to an upscale and highly educated audience - business travelers. ClearVision's promise to advertisers is an unsurpassed, engaged brand experience within the airport environment, and our kickoff roadshow to Madison Avenue was highly encouraging as brands, advertisers and media planners/buyers were thrilled with the reach and engagement ClearVision provides," said Henry Mauriss, CEO ClearVision/ConnectiVISION.
About connectiVISION Digital Networks
connectiVISION is a revolutionary digital media company that is transforming the digital media landscape with one of the most dynamic away from home television networks ever launched. The company's television content strategy provides Fortune 500 brands and advertisers with optimal engagement and consumer interaction. Visit www.connectivision.com to learn more.
About Clear Channel Airports
Dedicated to airport advertising for more than 37 years, Clear Channel Airports is the premier innovator of contemporary display concepts. The Company, a division of Clear Channel Outdoor Holdings, Inc. (NYSE: CCO), one of the world's largest outdoor advertising companies, currently operates more than 275 airport programs across the globe and has a presence in 32 of the top 50 U.S. markets with major airports. More information can be found on Clear Channel Airports and Clear Channel Outdoor by visiting www.clearchannelairports.com and www.clearchanneloutdoor.com.
About Clear Channel Outdoor Holdings, Inc.
Clear Channel Outdoor Holdings, Inc., (NYSE: CCO) one of the world's largest outdoor advertising companies, reaches approximately 141 million people in the United States and approximately 374 million internationally, with more than 750,000 displays in over 40 countries across five continents, including 48 of the 50 largest markets in the United States. Clear Channel Outdoor Holdings offers many types of displays across its global platform to meet the advertising needs of its customers. This includes a growing digital platform that now offers over 1000 digital displays across 37 U.S. markets. Clear Channel International operates in 30 countries across Asia, Australia and Europe in a wide variety of formats.
Certain statements in this release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Press Contact:
David Grabert
Clear Channel Outdoor
(212) 812-0089
DavidGrabert@clearchannel.com
SOURCE Clear Channel Outdoor Holdings, Inc.
That's an interesting theory.
There are plenty of buyers -- even with reports of brokers making it difficult to buy. Hopefully all those situations have been cleared up. I know I was a victim of a broker (who blamed the MM) not letting my order go fully through and showing a far lower bid than buy that was outstanding. Games -- on purpose or incompetence? Everyone can decide that for themselves. It does seem shares are hard to find because no one wants to sell when they can hold for larger gains.
I feel we'll surpass last year's highs in the .05s -- based upon the technicals of the chart combined with the fundamentals of asset valuation growth. That's the prettiest chart I've seen in a long, long time!
As far as Collins' shares (or any other insiders), keep in mind those shares are restricted. Collins can't sell until mid summertime, at the soonest. IMO, by then, with the K and H1 under our belt, we'll be sitting quite pretty -- possibly over a dime! (depending upon what the overall market does and what the financials show).
It's been awhile since I've been so anxious to start the week and finish the weekend. Is it Monday yet?!
Go PNCH!
#8 on the popular list. :)
:)
Astute observation skills you have there, soldier!
(I think I must be typing my replies with disappearing keystrokes!)
Precisely what I was thinking. I think this run will push up towards .10 this time, if history repeats. We can do another multi-bagger from this level, which is a higher level than the one from which it ran last time.
You've got to ask yourself...why the recent run-up -- particularly so close to the K, the Q and the shareholder's meeting mid April. Is it all speculation or does somebody know something?! By now, somebody has a sense of what the annual numbers are, at least! And based upon the buying these last couple of weeks, there is a good chance they are good.
We've all seen the PRs. We can speculate and we can do the potential math. It's not a matter of if revenues will come...it's a matter of how much! And if expenses are held in check...well, the sky is the limit here.
I am all for paying people with stock -- let them really have skin in the game. There is no reason people who do the work shouldn't reap the rewards. That includes investors -- as far as skin in the game goes. If no skin in the game, no need to post right?!
I know about the requirements. I also know there are exceptions to the normal rules. Other than that, I do not know where things stand or if it makes good financial sense to uplist at this time.
I know it will cost us more to uplist, but it will also open us up to new investors. Hopefully a good trade-off for a stock that has intentions to move to the Nasdaq one day. You've got to spend money to make money (though some folks here seem to want only to make money and not spend a dime!) .
Pieces are falling into place.
Connectivision --
Clearvision --
Travel Tech --
Punch TV --
and more...
All adding revenues. All helping us grow. We should start to see the results in each successive Q -- possibly starting with the K, but definitely with the Qs.
GLTU
I'd say Steve has better things to do these days -- with the release of financials and the shareholder's meeting coming up.
Plus, what's to say until it's a done deal? He already told us he was contacted about it. He didn't have to mention that, but he did. Personally, I wish he'd say less than he does -- too many out here twist his words around. Actions speak louder than words anyway.
It's nice to see the regular boys out here, causing mischief as they do. Tells me PNCH has caught your attention yet again. Why is that?? ! Oh yeah....megagains!
Jump on the maglev or get left behind -- it's your call.
Go PNCH!
I love how people throw around the term 'toxic financing'. Labeling something as 'toxic' assumes it is a bad thing. Financing, of course, is a good thing -- particularly if a business is new and/or growing.
The term 'toxic' only applies IF the share price is not rising, if the asset valuation is not growing. That's not exactly the case these days, is it?
The phrase 'toxic financing' can only be stated with certainty after all transactions are concluded and the PPS at that time is known. Who knows...your 'toxic financing' might just be the exact opposite of what you seem to think it is.
Shouldn't people willing to take the risk to lend to a start-up be compensated well for their efforts? Shareholders here are taking a risk. Should we not be compensated well for our efforts? This isn't a charity. We're all in the business of making money. Hopefully!
Those using terms such as 'toxic financing' are showing their ignorance as to what is really going on here. It only makes their intentions suspect, at best. IMO
I've got low volume on all my stocks -- thereby allowing games to be played more easily. Apparently, some folks are taking today off! It's the end of quarter for my kids and they are already out of school. Next week, volume will be even worse across-the-board because of spring/Easter breaks. IMO
Let's see where PNCH stands after financials and by meeting time -- say mid April-ish.
That said, you never know what could happen during power hour! PNCH does buck the trend sometimes.
Such a pretty chart, isn't it? All charts should smile like this one!
$$$$$$$$$$$$$$$$$$$ PNCH $$$$$$$$$$$$$$$$$$$$$$$$
Silver + Gold = GREEN
You mean the maglev?! ;) :D
The projection is not just FORWARD. It's UP and FORWARD!!!
Only so many days left before the K. Only so many days before the Q. Only so many days before the shareholder's meeting.
Go PNCH!
You know as well as I do that the increase is to be able to grow the business. Operations cost money before they make money.
Quit trying to eat your dessert first...take your time, have some pizza!
And feel free to remove your ridiculous stickies while you're at it!
Go PNCH!
The reason for the increase in SS, as we all know, is the acquistion of Punch TV to the asset mix.
Yes shares are higher. And yes, asset valuation is far higher too! Steve was here. He spoke to this. It has been PR'd. It's out there for everyone to see.
But for those who do not wish or choose to look to far into their investments...there's always the stickies. Presuming of course they are used for their intended purpose -- to sticky important information from the CEO and press releases -- not for the whimsical opinions of mods.
@surf -- nothing wrong with taking profits when you've got them. I bought a whole lot more recently, hopefully helped some others take their profits. Glad to see you held on to some for the bigger gains we all know are coming.
GLTAL